Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2023 Q1- Text added to 2023 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
calendar, Carlo, checkpoint, Drapkin, Dylla, inhibitor, Kimberlee, Monte, MSD, neuromuscular, panel, pembrolizumab, qualitative, referenced, regain, Scott, simulation, unilaterally
Removed:
adjustment, ASU, authority, back, biopharmaceutical, borrowing, building, cease, challenging, Codification, commercializing, competing, consideration, consultant, covered, credit, curtail, dementia, designated, difficult, discontinue, eliminate, EMA, emergence, enable, encounter, enhancing, enrollment, European, expand, expanding, FDA, forced, frontotemporal, guidance, headcount, history, impacted, infusion, initiated, involving, length, lobar, pandemic, planned, profitability, pursuit, quality, receipt, recognition, recommendation, reduction, registration, Richard, secure, seeking, selling, sooner, successful, sustain, unforeseen, utilize, worsening
Valuein 2023 Q1 filing- Value in 2023 Q2 filing
Original filings
Filing view